Sign In
Buy CRSP
$52.08
+0.0600 (+0.115%)
At Close: Jun 03, 2026
Up 24% In A Month, Will CRISPR Stock Continue To See Higher Levels?
07:00am, Wednesday, 22'nd Jun 2022
CRISPR Therapeutics stock (NASDAQ: CRSP), a biotechnology gene-editing company focused on developing gene-based medicines for human diseases, has risen a solid 24% in a month, outperforming the broade
CRISPR Therapeutics AG (CRSP) Moves 8.3% Higher: Will This Strength Last?
11:43am, Monday, 20'th Jun 2022 Zacks Investment Research
CRISPR Therapeutics AG (CRSP) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further streng
CRISPR Therapeutics AG (CRSP) Moves 8.3% Higher: Will This Strength Last?
09:20am, Monday, 20'th Jun 2022
CRISPR Therapeutics AG (CRSP) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further streng
Why Bluebird Bio Skyrocketed Today
04:03pm, Friday, 17'th Jun 2022 The Motley Fool
Management's comments at a virtual conference went over quite well.
3 Reason Why This Analyst Says CRISPR Therapeutics Is A Biotech Winner
03:04pm, Friday, 17'th Jun 2022 Benzinga
CRISPR Therapeutics AG (NASDAQ: CRSP) has a diversified pipeline with potential CTX001 commercialization and CTX110 potential approval expected in 2024, according to BMO Capital Markets.
The CRISPR Th
3 Bargain Stocks You Can Buy Today and Hold Forever
12:30pm, Friday, 17'th Jun 2022 The Motley Fool
These companies have become great deals because of the market downturn.
3 Reason Why This Analyst Says CRISPR Therapeutics Is A Biotech Winner
11:11am, Friday, 17'th Jun 2022
CRISPR Therapeutics AG (NASDAQ: CRSP) has a diversified pipeline with potential CTX001 commercialization and CTX110 potential approval expected in 2024, according to BMO Capital Markets. The CRISPR Th
CRISPR Therapeutics AG (CRSP) Management Presents at Goldman Sachs 43rd Annual Global Healthcare Conference (Transcript)
05:09pm, Wednesday, 15'th Jun 2022
CRISPR Therapeutics AG (NASDAQ:CRSP ) Goldman Sachs 43rd Annual Global Healthcare Conference June 15, 2022 12:20 PM ET Company Participants Salveen Richter - Goldman Sachs Conference Call Participants
2 Top Biotech Stocks Ready for Bull Runs
02:30pm, Wednesday, 15'th Jun 2022 The Motley Fool
The market hasn't been kind to these two stocks lately.
Final Trades: Boeing, Charles Schwab, Crispr Therapeutics & more
01:45pm, Wednesday, 15'th Jun 2022
The "Halftime Report" traders give their top picks to watch for the second half.
Is This The Dividend Trade Of The Decade?
09:09am, Wednesday, 15'th Jun 2022 Investing.comAnalysts Consider CRISPR Therapeutics' Blood Disorder Trial Data Encouraging, Impressive
01:29pm, Monday, 13'th Jun 2022
CRISPR Therapeutics (NASDAQ: CRSP) presented results from its ongoing Phase 1 COBALT-LYM CTX130 (exa-cel) trial, an allogeneic CAR-T cell therapy targeting CD70 for solid tumors and certain hematolog
2 Hot Stocks to Buy and Hold Until You Retire
12:15pm, Sunday, 12'th Jun 2022 The Motley Fool
What market downturn? These stocks are bucking the trend.
CRISPR Therapeutics Presents Positive Results from its Phase 1 COBALT™-LYM Trial of CTX130™ in Relapsed or Refractory T Cell Malignancies at the 2022 European Hematology Association (EHA) Congress
03:00pm, Saturday, 11'th Jun 2022 GlobeNewswire Inc.
-70% overall response rate (ORR) and 30% complete response (CR) rate in peripheral T-cell lymphoma (PTCL) and cutaneous T cell lymphoma (CTCL) at Dose Level 3 (DL3) and above; clinical benefit for 90%
5 Health Care Stocks Cathie Wood Favors
04:07pm, Thursday, 09'th Jun 2022
Catherine Wood (Trades, Portfolio), the founder, chief investment officer and CEO of ARK Investment Management, has made a name for herself through investing in “disruptive innovation” stocks.
